666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients

Sarah P. Blagden, David J. Harrison, T.R. Jeffry Evans et al.|Annals of Oncology|2024

Cited by 3